Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Role of pentoxifylline in non-alcoholic fatty liver disease in high-fat diet-induced obesity in mice

Full text
Acedo, Simone Coghetto [1] ; Caria, Cintia Rabelo e Paiva [1] ; Ferreira Gotardo, Erica Martins [1] ; Pereira, Jose Aires [1] ; Pedrazzoli, Jose [1] ; Ribeiro, Marcelo Lima [1] ; Gambero, Alessandra [1]
Total Authors: 7
[1] Sao Francisco Univ Med Sch, Clin Pharmacol & Gastroenterol Unit, Av Sao Francisco de Assis 218, BR-12916900 Braganca Paulista, SP - Brazil
Total Affiliations: 1
Document type: Journal article
Source: WORLD JOURNAL OF HEPATOLOGY; v. 7, n. 24, p. 2551-2558, OCT 28 2015.
Web of Science Citations: 7

AIM: To study pentoxifylline effects in liver and adipose tissue inflammation in obese mice induced by high-fat diet (HFD). METHODS: Male swiss mice (6-wk old) were fed a highfat diet (HFD; 60% kcal from fat) or AIN-93 (control diet; 15% kcal from fat) for 12 wk and received pentoxifylline intraperitoneally (100 mg/kg per day) for the last 14 d. Glucose homeostasis was evaluated by measurements of basal glucose blood levels and insulin tolerance test two days before the end of the protocol. Final body weight was assessed. Epididymal adipose tissue was collected and weighted for adiposity evaluation. Liver and adipose tissue biopsies were homogenized in solubilization buffer and cytokines were measured in supernatant by enzyme immunoassay or multiplex kit, respectively. Hepatic histopathologic analyses were performed in sections of pa raformaldehyde-fixed, paraffin-embedded liver specimens stained with hematoxylin-eosin by an independent pathologist. Steatosis (macrovesicular and microvesicular), ballooning degeneration and inflammation were histopathologically determined. Triglycerides measurements were performed after lipid extraction in liver tissue. RESULTS: Pentoxifylline treatment reduced microsteatosis and tumor necrosis factor (TNF)-alpha in liver (156.3 +/- 17.2 and 62.6 +/- 7.6 pg/mL of TNF-alpha for non-treated and treated obese mice, respectively; P < 0.05). Serum aspartate aminotransferase levels were also reduced (23.2 +/- 6.9 and 12.1 +/- 1.6 U/L for nontreated and treated obese mice, respectively; P < 0.05) but had no effect on glucose homeostasis. In obese adipose tissue, pentoxifylline reduced TNF-alpha (106.1 +/- 17.6 and 51.1 +/- 9.6 pg/mL for non-treated and treated obese mice, respectively; P < 0.05) and interleukin-6 (340.8 +/- 51.3 and 166.6 +/- 22.5 pg/mL for non-treated and treated obese mice, respectively; P < 0.05) levels; however, leptin (8.1 +/- 0.7 and 23.1 +/- 2.9 ng/mL for non-treated and treated lean mice, respectively; P < 0.05) and plasminogen activator inhibitor-1 (600.2 +/- 32.3 and 1508.6 +/- 210.4 pg/mL for non-treated and treated lean mice, respectively; P < 0.05) levels increased in lean adipose tissue. TNF-alpha level in the liver of lean mice also increased (29.6 +/- 6.6 and 75.4 +/- 12.6 pg/mL for non-treated and treated lean mice, respectively; P < 0.05) while triglycerides presented a tendency to reduction. CONCLUSION: Pentoxifylline was beneficial in obese mice improving liver and adipose tissue inflammation. Unexpectedly, pentoxifylline increased pro-inflammatory markers in the liver and adipose tissue of lean mice (AU)

FAPESP's process: 11/00518-4 - Hepatic inflammation: role of inate immune system ánd adipose tissue ánd, pharmacologycal characterization of toll-like receptors ánd penthoxyphylline
Grantee:Simone Coghetto Acedo Batista
Support type: Scholarships in Brazil - Doctorate